Rigacci L, Puccini B, Iovino L, Martelli M, Finolezzi E, DI Lollo S, Doria M, Bosi A
Hematology Department Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
J Chemother. 2011 Aug;23(4):227-31. doi: 10.1179/joc.2011.23.4.227.
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Gene-expression profiling in DLCBL has brought insight into the biological heterogeneity of the disease. Two major subgroups have been identified: germinal center B (GCB) cell and non-germinal center (non-GCB). The aim of this study was to define retrospectively by immunohistochemistry the bcell origin of 69 patients treated with R-CHOP14 and to evaluate if dose-dense therapy could improve their clinical outcome. According to immunohistochemistry analysis 28 patients were derived from germinal center and 41 from non-germinal center. After a median period of observation of 46 months (range 3-101 months) the overall survival (OS) was 75% and progression-free survival (PFS) was 53% and no differences were observed according to cell origin. In conclusion, we can point out that intensification could enhance the efficacy of the R-CHOP regimen and improve overall survival in patients with non germinal lymphoma.
弥漫性大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤类型。DLBCL的基因表达谱分析为该疾病的生物学异质性提供了深入见解。已确定两个主要亚组：生发中心B（GCB）细胞和非生发中心（非GCB）。本研究的目的是通过免疫组织化学回顾性确定69例接受R-CHOP14治疗患者的B细胞起源，并评估剂量密集疗法是否能改善其临床结局。根据免疫组织化学分析，28例患者起源于生发中心，41例起源于非生发中心。经过中位46个月（范围3 - 101个月）的观察期，总生存期（OS）为75%，无进展生存期（PFS）为53%，未观察到根据细胞起源的差异。总之，我们可以指出强化治疗可提高R-CHOP方案的疗效并改善非生发中心淋巴瘤患者的总生存期。
